Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMA1-DiCo + GLA-SE
- Development stage
- Unknown
- Lead developer
- European Vaccine Initiative
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AMA1-DiCo + GLA-SE is a malaria vaccine candidate targeting the blood stage of *Plasmodium falciparum*. The formulation consists of three recombinant variants of the apical membrane antigen 1 (AMA1), designed to cover the extensive polymorphism found in natural parasite populations. These three "Diversity Covering" (DiCo) proteins are combined to induce broad immune responses against multiple strains. The vaccine is adjuvanted with glucopyranosyl lipid adjuvant–stable emulsion (GLA-SE), a synthetic TLR4 agonist that enhances Th1-type immune responses and antibody production. Clinical trials have shown that this combination is safe and immunogenic in both malaria-naive and malaria-exposed adults, with higher IgG responses observed when using GLA-SE compared to aluminum-based adjuvants[1][2][5][8]. The primary indication is for prevention of malaria caused by *P. falciparum*.
- Other names
- Plasmodium falciparum Apical Membrane Antigen 1 Diversity Covering vaccine with GLA-SE adjuvantPfAMA1 DiCo + GLA-SE
02
Targets
TLR4 (Toll-like receptor 4)AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on AMA1-DiCo + GLA-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMA1-DiCo + GLA-SE.